# Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Clinical trial · COMPASS Pathways

- Archive id: nct:NCT05711940
- Published: 2023-02-03
- Venue: ClinicalTrials.gov
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT05711940
- Source URL: https://clinicaltrials.gov/study/NCT05711940
- Provenance: clinicaltrials

## Abstract

Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)

_Abstract reproduced under ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters._

## Trial details

- status: ACTIVE_NOT_RECRUITING
- phase: PHASE3
- study type: INTERVENTIONAL
- enrollment: 572
- sponsor: COMPASS Pathways
- conditions: Treatment Resistant Depression
- interventions: DRUG: Psilocybin
- start date: 2023-02-14
- start date type: ACTUAL
- primary completion date: 2025-11-13
- has results: false
- data source: ClinicalTrials.gov
- data processed: 2026-10-29T09:00:05
- modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters

Topics: [Novel Psychiatric Therapeutics](https://space-kitty.com/topics/psychiatric-therapeutics)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.